Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 57

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 57
---
|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.19 |     | Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 10.3 to the registrant’s Report on Form 6-K furnished to the SEC on January 16, 2024)                                                                                                                                                     |
| 10.20 |     | Form of Registration Rights Agreement (incorporated herein by reference to Exhibit 10.4 to the registrant’s Report on Form 6-K furnished to the SEC on January 16, 2024)                                                                                                                                          |
| 10.21 |     | Form of Placement Agent Agreement (incorporated herein by reference to Exhibit 10.5 to the registrant’s Report on Form 6-K furnished to the SEC on January 16, 2024)                                                                                                                                              |
| 10.22 |     | Form of License Agreement effective as of January 15, 2024, by and between BIRAD Research and Development Company Ltd. and Clearmind Medicine Inc. (incorporated herein by reference to Exhibit 4.18 to the registrant’s Annual Report on Form 20-F filed with the SEC on January 22, 2025)                       |
| 10.23 |     | Form of License Agreement dated March 19, 2024, by and between Yissum Research and Development Company of the Hebrew University of Jerusalem and Clearmind Medicine Inc. (incorporated herein by reference to Exhibit 4.19 to the registrant’s Annual Report on Form 20-F filed with the SEC on January 22, 2025) |
| 10.24 |     | License Agreement dated March 31, 2024, by and between Yissum Research and Development Company of the Hebrew University of Jerusalem and Clearmind Medicine Inc. (incorporated herein by reference to Exhibit 4.20 to the registrant’s Annual Report on Form 20-F filed with the SEC on January 22, 2025)         |
| 10.25 |     | Form of Convertible Promissory Note (incorporated herein by reference to Exhibit 4.1 to the registrant’s Report on Form 6-K furnished to the SEC on September 17, 2025)                                                                                                                                           |
| 10.26 |     | Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the registrant’s Report on Form 6-K furnished to the SEC on